Synexus Clinical Research GmbH
- Address
- lock Available on a paid plan
Nervous System Diseases and Chronic Neuropathic Pain Research
At Synexus Clinical Research GmbH in Frankfurt, clinical research in Nervous System Diseases focuses on moderate to severe chronic peripheral neuropathic pain, including pain linked to postherpetic neuralgia and peripheral nerve injury. The studies are designed to assess whether new treatment options can better reduce pain and improve relief for people living with persistent nerve-related pain.
- Evaluating a new therapy for chronic neuropathic pain
- Comparing treatment effects against placebo
- Measuring changes in daily pain intensity
This work reflects a focused effort to improve symptom control and support better care for patients with long-lasting nerve pain.
Nutritional and Metabolic Diseases and Obesity Studies
Clinical trials in Nutritional and Metabolic Diseases at the Frankfurt site are centered on obesity and related health risks. The research is aimed at understanding whether new approaches can support weight management while also helping to evaluate broader health outcomes tied to excess body weight.
- Studying a potential treatment for obesity
- Assessing cardiovascular safety and overall health impact
- Supporting research into improved long-term disease management
These trials add to the site’s work on metabolic health, with attention to both effectiveness and safety in people affected by overweight or obesity.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 12 of 15 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Synexus Clinical Research GmbH
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A parallel-group treatment, proof-of-concept Phase 2, multicenter, double-blind, randomized 2 arm clinical trial to investigate the efficacy and safety of subcutaneous NT 201 injections compared with placebo injections in decreasing pain intensity in male and female participants aged 18 years and older with moderate or severe chronic neuropathic pain due to postherpetic neuralgia or peripheral nerve injury. | Merz Therapeutics GmbH | Phase II | Not Recruiting | Oct 2023 | Jun 2025 |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paracetamol | 2 | Unknown | 2023-10-17 | 2024-02-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.